top of page

Crafting a Cross-Species, Large Genomic Model

Decoding the Language of Life

Cognit is crafting a cross-cell, cross-species Large Genomic Model (LGM) that enables high-resolution functional genomics through closed-loop, in-silico, gene and cell engineering, redefining the paradigms in genomics research. 

Thanks for submitting!
Screenshot 2023-10-18 at 2.59.42 PM.png

Cognit's Focus

Screenshot 2024-01-18 at 4.03.36 PM.png
Screenshot 2024-01-10 at 5.26.28 PM.png
Screenshot 2023-10-18 at 3.33.56 PM.png

Industries Empowered by Cognit to Build on Our AI Platform

Screenshot 2023-10-18 at 3.24.18 PM.png
Screenshot 2023-10-18 at 3.04.47 PM.png
Screenshot 2023-10-18 at 3.24.35 PM.png
Screenshot 2023-10-18 at 3.04.36 PM.png
Screenshot 2023-10-18 at 3.05.47 PM.png

The current state of drug discovery is inefficient and expensive. It takes an average of 12 years and $2.6 billion to bring a new drug to market.

This is due in part to the fact that drug discovery is largely a trial-and-error process. Researchers must first identify a target gene, then develop a drug that can modulate that gene's expression. This process is often time-consuming and expensive, and it can be difficult to predict which drugs will be effective.

Cognit Edge

High-Resolution Genomics: We've transcended traditional views, achieving significant insights into genetic interactions.

Holistic Tumor Analysis: Our integrated approach offers a comprehensive view of tumor biology, predicting behavior with precision.

Targeted Therapies: We're in the process of identifying and validating therapeutic targets with high accuracy.


Combatting Drug Resistance: Our strategies forecast and counteract drug resistance, ensuring sustained efficacy.

Streamlined Drug Development: Efficiency and cost-effectiveness are at the heart of our optimized processes.

Personalized Therapies: Tailoring treatments to individual tumor profiles is now a reality.


Synthetic Lethality: We're in the process of identifying gene combinations for enhanced tumor cell eradication.

Decoding the Genome: Illuminating previously unknown genomic regions, we're broadening our understanding of tumorigenesis.


Safety Assured: Predicting and validating off-target effects, we prioritize patient safety.

Predicting Tumor Evolution: Our tools simulate tumor evolution, keeping us steps ahead.

Revolutionized Clinical Trials: Our data-driven approach is setting new standards for trial success.

bottom of page